CRIS : Summary for Curis, Inc. - Yahoo Finance

U.S. Markets close in 3 hrs 20 mins

Curis, Inc. (CRIS)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.94-0.14 (-4.55%)
As of 12:37 PM EST. Market open.
People also watch:
ARQLCERSAGENCYTRARRY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close3.08
Open3.06
Bid2.93 x 1300
Ask2.94 x 200
Day's Range2.91 - 3.08
52 Week Range1.25 - 3.72
Volume284,946
Avg. Volume759,357
Market Cap413.21M
Beta2.50
PE Ratio (TTM)-6.10
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube22 hours ago

    ETFs with exposure to Curis, Inc. : December 8, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Curis, Inc. Here are 5 ETFs with the largest exposure to CRIS-US. Comparing the performance and risk of Curis, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Curis, Inc. breached its 50 day moving average in a Bearish Manner : CRIS-US : December 1, 2016
    Capital Cube8 days ago

    Curis, Inc. breached its 50 day moving average in a Bearish Manner : CRIS-US : December 1, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Curis, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)

  • GlobeNewswire11 days ago

    Curis Announces Full Approval of Roche’s Erivedge® in the European Union

    LEXINGTON, Mass., Nov. 28, 2016-- Curis, Inc., a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of cancer, today announced ...